M M Agarwal1, P F Hughes, J Punnose, M Ezimokhai. 1. Department of Pathology, Faculty of Medicine, UAE University, Al Ain, United Arab Emirates. magarwal@emirates.net.ae
Abstract
AIMS: Screening every pregnant woman for gestational diabetes mellitus (GDM), as widely recommended for high-incidence populations, strains the healthcare system excessively. This study investigated the value of fasting plasma glucose (FPG) as an alternative to the more cumbersome oral glucose tolerance test (OGTT). METHODS: One thousand six hundred and forty-four pregnant women in a multi-ethnic, high-risk population were evaluated by the FPG as a screening test among two principal subgroups, i.e. women (n = 1276) at risk for GDM on clinical grounds and those women (n = 368) with a positive post 50-g, 1-h plasma glucose challenge test (GCT). Two threshold values for FPG 'ruled in or ruled out' a GDM diagnosis, which was confirmed by the 3-h, 100-g OGTT, using Carpenter's modified criteria as the 'gold standard'. RESULTS: In the women with a positive clinical history, at an optimal cut-off value of FPG < 4.4 mmol/l to rule out GDM; a sensitivity of 94.7% was achieved, 21 (1.6%) women being false negatives. Using a FPG > or = 5.3 mmol/l to rule in GDM; the specificity was 94.0% with 53 (4.2%) women being classified as false positives. FPG would have eliminated need for the OGTT in 50.9% pregnant women (misclassification rate 5.8%). In the positive GCT group, using similar cut-offs for FPG, a sensitivity of 96.6% and specificity of 90.8% was achieved with a potential to avoid 51.6% OGTTs (misclassification rate 7.3%). The positive predictive value of the GCT was 31.8% compared to 80.2% for FPG at 5.3 mmol/l. CONCLUSIONS: While previously neglected as a screening test for GDM, in selected high-risk populations the FPG offers a potentially simple, practical algorithm to screen for GDM by being cost-effective and patient friendly. A wider application should be explored.
AIMS: Screening every pregnant woman for gestational diabetes mellitus (GDM), as widely recommended for high-incidence populations, strains the healthcare system excessively. This study investigated the value of fasting plasma glucose (FPG) as an alternative to the more cumbersome oral glucose tolerance test (OGTT). METHODS: One thousand six hundred and forty-four pregnant women in a multi-ethnic, high-risk population were evaluated by the FPG as a screening test among two principal subgroups, i.e. women (n = 1276) at risk for GDM on clinical grounds and those women (n = 368) with a positive post 50-g, 1-h plasma glucose challenge test (GCT). Two threshold values for FPG 'ruled in or ruled out' a GDM diagnosis, which was confirmed by the 3-h, 100-g OGTT, using Carpenter's modified criteria as the 'gold standard'. RESULTS: In the women with a positive clinical history, at an optimal cut-off value of FPG < 4.4 mmol/l to rule out GDM; a sensitivity of 94.7% was achieved, 21 (1.6%) women being false negatives. Using a FPG > or = 5.3 mmol/l to rule in GDM; the specificity was 94.0% with 53 (4.2%) women being classified as false positives. FPG would have eliminated need for the OGTT in 50.9% pregnant women (misclassification rate 5.8%). In the positive GCT group, using similar cut-offs for FPG, a sensitivity of 96.6% and specificity of 90.8% was achieved with a potential to avoid 51.6% OGTTs (misclassification rate 7.3%). The positive predictive value of the GCT was 31.8% compared to 80.2% for FPG at 5.3 mmol/l. CONCLUSIONS: While previously neglected as a screening test for GDM, in selected high-risk populations the FPG offers a potentially simple, practical algorithm to screen for GDM by being cost-effective and patient friendly. A wider application should be explored.
Authors: Delia Bogdanet; Michelle Toth Castillo; Helen Doheny; Louise Dervan; Miguel-Angel Luque-Fernandez; Jose A Halperin; Paula M O'Shea; Fidelma P Dunne Journal: J Clin Med Date: 2022-07-04 Impact factor: 4.964
Authors: Kaat Beunen; Astrid Neys; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Nele Roggen; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Annick Van Den Bruel; Anne Loccufier; Annouschka Laenen; Roland Devlieger; Chantal Mathieu; Katrien Benhalima Journal: Acta Diabetol Date: 2021-11-01 Impact factor: 4.280